NCT04907084View on ClinicalTrials.gov

Serine and Fenofibrate Study in Patients With MacTel Type 2

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Macular Telangiectasia Type 2
Interventions
DIETARY_SUPPLEMENT

Serine

Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

DRUG

Fenofibrate

Fenofibrate 160mg pill, taken orally

Trial Locations (9)

30322

Emory University, Atlanta

37922

Southeastern Retina Associates, Knoxville

44122

Retina Associates of Cleveland, Cleveland

48105

Kellogg Eye Center, University of Michigan, Ann Arbor

53226

The Eye Institute, Medical College of Wisconsin, Milwaukee

77401

Retina Consultants of Texas, Bellaire

84132

Moran Eye Center, University of Utah, Salt Lake City

98104

University of Washington, Seattle

ECV2PD

Moorfields Eye Hospital, London

All Listed Sponsors
lead

The Lowy Medical Research Institute Limited

OTHER